By Colin Kellaher


Integra LifeSciences Holdings has agreed to buy ear, nose and throat (ENT) technology company Acclarent from a unit of Johnson & Johnson for $275 million in cash.

Integra on Wednesday said the deal, which expands its portfolio of ENT products and technologies, also includes an additional $5 million based on the achievement of certain regulatory milestones.

Princeton, N.J., medical-technology company Integra said Acclarent generated about $110 million in revenue in 2022.

Integra, which has forecast revenue of $1.54 billion to $1.55 billion for 2023, said it expects to complete the acquisition by the second quarter of 2024.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

12-13-23 0648ET